Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FX1KK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,245
Award facts
- Contract value 100% obligated
- $34,244.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $34.2K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 300 mg/2 ml auto-injector units. The contract, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, reflecting the vendor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's recently awarded single-award Indefinite Delivery Contract (IDC) with DLA under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $500M ceiling value and extends through December 31, 2036.
The PPV-G GEN V represents a $30.3B government-wide acquisition strategy designed to establish regional prime vendor contractors capable of supplying a comprehensive range of pharmaceutical products, biologics, and medical consumables to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group's established track record supplying specialty pharmaceuticals, biologics, and vaccines to military healthcare facilities positions it as a critical supplier within the federal pharmaceutical supply chain. The company will serve as the sole contractor on this delivery order, with no identified subcontractor relationships, and will fulfill DLA's recurring pharmaceutical supply needs through firm fixed-price delivery orders structured under the broader PPV-G GEN V framework.
Quick answers
Who was awarded contract SPE2DB26FX1KK?
SPE2DB26FX1KK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FX1KK worth?
The government has obligated $34,245 on SPE2DB26FX1KK.
Is contract SPE2DB26FX1KK an order under another contract?
Yes. SPE2DB26FX1KK is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1KK competed?
The extent of competition for SPE2DB26FX1KK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award